This infographic and the research mentioned had been funded by AstraZeneca. This content material is meant for US Healthcare Professionals solely.
TOURMALINE evaluated the security and efficacy of first-line durvalumab mixed with one in every of seven gemcitabine-based chemotherapy regimens in a near-real-world superior biliary tract most cancers (aBTC) inhabitants, together with contributors with poor prognosis. This infographic explores the first evaluation and what it means for a broader aBTC inhabitants.
You’ll be taught:
- How security held up throughout seven completely different gemcitabine-based regimens
- What occurred to infusion-related reactions when durvalumab infusion time was minimize from 60 to half-hour
- What the efficacy findings point out about durvalumab mixed with these regimens
- Whether or not the first evaluation helps this method in contributors with much less favorable prognosis
